Literature DB >> 3515312

Fluorinated quinolones. A review of their mode of action, antimicrobial activity, pharmacokinetics and clinical efficacy.

R Janknegt.   

Abstract

Quinolones, chemically related to nalidixic acid, have a strong and rapid bactericidal action against Gram-negative bacteria, including Ps. aeruginosa, some Mycobacteria, Legionella and Staphylococci. Streptococci and anaerobic bacteria are usually less sensitive. The quinolones exert their bactericidal action through inhibition of the enzyme DNA gyrase. Quinolones are absorbed for 50-100% from the gastro-intestinal tract, their volume of distribution is generally high (2 l/kg) and high concentrations are reached in almost all organs. The elimination half-lives range from 4 to 14 h. The efficacy of quinolones in urinary tract infections has been shown in many studies. They also seem to be effective in many serious infections. In animal studies their efficacy was generally equal or superior to aminoglycosides. Until now only mild and infrequent side effects have been reported.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3515312     DOI: 10.1007/bf01975473

Source DB:  PubMed          Journal:  Pharm Weekbl Sci        ISSN: 0167-6555


  98 in total

1.  Reduced enteral absorption of ciprofloxacin in the presence of antacids.

Authors:  G Höffken; K Borner; P D Glatzel; P Koeppe; H Lode
Journal:  Eur J Clin Microbiol       Date:  1985-06       Impact factor: 3.267

2.  Activities of newer quinolones against Legionella group organisms.

Authors:  D Greenwood; A Laverick
Journal:  Lancet       Date:  1983-07-30       Impact factor: 79.321

3.  The pharmacokinetics and tissue penetration of norfloxacin.

Authors:  Z N Adhami; R Wise; D Weston; B Crump
Journal:  J Antimicrob Chemother       Date:  1984-01       Impact factor: 5.790

4.  The clinical pharmacokinetics and tolerance of enoxacin in healthy volunteers.

Authors:  R Wolf; R Eberl; A Dunky; N Mertz; T Chang; J R Goulet; J Latts
Journal:  J Antimicrob Chemother       Date:  1984-09       Impact factor: 5.790

5.  In vitro activities of the spectinomycin analog U-63366 and four quinolone derivatives against Neisseria gonorrhoeae.

Authors:  M Peeters; E Van Dyck; P Piot
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

6.  Activity of ciprofloxacin (BAYo 9867) against Pseudomonas aeruginosa and ampicillin-resistant Enterobacteriaceae.

Authors:  C Roy; A Foz; C Segura; M Tirado; M Teixell; D Teruel
Journal:  Infection       Date:  1983 Nov-Dec       Impact factor: 3.553

7.  Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function--some preliminary results.

Authors:  P J Hughes; D B Webb; A W Asscher
Journal:  J Antimicrob Chemother       Date:  1984-05       Impact factor: 5.790

8.  Comparative study using norfloxacin and amoxycillin in the treatment of complicated urinary tract infections in geriatric patients.

Authors:  D A Leigh; E C Smith; J Marriner
Journal:  J Antimicrob Chemother       Date:  1984-05       Impact factor: 5.790

9.  In-vitro activity of enoxacin (CL-919), a new quinoline derivative, compared with that of other antimicrobial agents.

Authors:  R Wise; J M Andrews; G Danks
Journal:  J Antimicrob Chemother       Date:  1984-03       Impact factor: 5.790

10.  Open, prospective study of the clinical efficacy of ciprofloxacin.

Authors:  C A Ramirez; J L Bran; C R Mejia; J F Garcia
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

View more
  14 in total

Review 1.  Clinical role of protein binding of quinolones.

Authors:  Eugénie Bergogne-Bérézin
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 2.  Mycobacteria and the new quinolones.

Authors:  D C Leysen; A Haemers; S R Pattyn
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

3.  In vitro susceptibility of Neisseria gonorrhoeae to RO 23-6240 and ciprofloxacin.

Authors:  S S Kaukoranta-Tolvanen; O V Renkonen
Journal:  Eur J Clin Microbiol       Date:  1987-06       Impact factor: 3.267

4.  Effect of food on enoxacin absorption.

Authors:  A A Somogyi; F Bochner; J A Keal; P E Rolan; M Smith
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

5.  Ciprofloxacin absorption in different regions of the human gastrointestinal tract. Investigations with the hf-capsule.

Authors:  S Harder; U Fuhr; D Beermann; A H Staib
Journal:  Br J Clin Pharmacol       Date:  1990-07       Impact factor: 4.335

6.  Oral pharmacokinetics and ascitic fluid penetration of ofloxacin in cirrhosis.

Authors:  C Silvain; S Bouquet; J P Breux; B Becq-Giraudon; M Beauchant
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 7.  Pharmacokinetics of ciprofloxacin.

Authors:  T Bergan; A Dalhoff; R Rohwedder
Journal:  Infection       Date:  1988       Impact factor: 3.553

Review 8.  Clinical pharmacokinetics of the newer antibacterial 4-quinolones.

Authors:  M Neuman
Journal:  Clin Pharmacokinet       Date:  1988-02       Impact factor: 6.447

Review 9.  Ofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J P Monk; D M Campoli-Richards
Journal:  Drugs       Date:  1987-04       Impact factor: 9.546

Review 10.  Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; J P Monk; A Price; P Benfield; P A Todd; A Ward
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.